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Abstract
Background: Fragile X syndrome (FXS) is a single-gene disorder that is the most common heritable cause of intellectual
disability and the most frequent monogenic cause of autism spectrum disorders (ASD). FXS is caused by an expansion of
trinucleotide repeats in the promoter region of the fragile X mental retardation gene (Fmr1). This leads to a lack of fragile
X mental retardation protein (FMRP), which regulates translation of a wide range of messenger RNAs (mRNAs).
The extent of expression level alterations of synaptic proteins affected by FMRP loss and their consequences on
synaptic dynamics in FXS has not been fully investigated.
Methods: Here, we used an Fmr1 knockout (KO) mouse model to investigate the molecular mechanisms underlying
FXS by monitoring protein expression changes using shotgun label-free liquid-chromatography mass spectrometry
(LC-MSE) in brain tissue and synaptosome fractions. FXS-associated candidate proteins were validated using selected
reaction monitoring (SRM) in synaptosome fractions for targeted protein quantification. Furthermore, functional
alterations in synaptic release and dynamics were evaluated using live-cell imaging, and interpretation of synaptic
dynamics differences was investigated using electron microscopy.
Results: Key findings relate to altered levels of proteins involved in GABA-signalling, especially in the cerebellum.
Further exploration using microscopy studies found reduced synaptic vesicle unloading of hippocampal neurons
and increased vesicle unloading in cerebellar neurons, which suggests a general decrease of synaptic transmission.
Conclusions: Our findings suggest that FMRP is a regulator of synaptic vesicle dynamics, which supports the role of
FMRP in presynaptic functions. Taken together, these studies provide novel insights into the molecular changes
associated with FXS.
Keywords: Fragile X syndrome (FXS), Synaptic transmission, Mass spectrometry (MS), Quantitative live-cell
imaging, Electron microscopy
Background
Fragile X syndrome (FXS, OMIM: #300624) is a single-
gene disorder causing a heritable form of mental impair-
ment (WHO, 1996), with a prevalence in males ranging
from 1/4000 to 1/5161 [1, 2]. Core cognitive deficits
found in FXS-patients include problems with short-term
and working memory, executive function deficits and
mathematical and visuospatial difficulties [3]. Furthermore,
60–74 % of male FXS patients meet the criteria for autism
spectrum disorder (ASD), and 2–6 % of ASD patients are
identified to suffer from FXS [4, 5]. In spite of the clear
monogenetic cause of FXS, the cellular consequences of
fragile X mental retardation protein (FMRP) depletion are
widespread and remain poorly understood. FMRP is
known for its role in messenger RNA (mRNA) binding,
transport activity and subsequent translation regulation
upon metabotropic glutamate receptor 5 (mGluR5) stimu-
lation [6, 7]. Synaptic dysfunction would be expected both
in the pre- and postsynaptic regions. The systems found to
be affected at the presynapse include synaptic vesicles [8]
and plasticity via short-term depression [9, 10]. Despite the
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indication of synaptic differences in the pathogenesis of
FXS, the underlying mechanisms of synaptic dysfunction
in FXS remain to be investigated.
In this study, a fragile X mental retardation 1 gene
(Fmr1) KO mouse model was used to study synaptic
changes in the hippocampus and cerebellum. In the first
part, both brain tissue and synaptosomes were subjected to
molecular profiling analyses using a combination of liquid-
chromatography mass spectrometry (LC-MSE) and se-
lected reaction monitoring mass spectrometry (SRM-MS)
to detect and validate protein changes (Fig. 1). We found
that in the absence of FMRP, most of the protein changes
occurred at the synapse, which is in line with previous
studies indicating differences in signal transduction,
neuronal development and GABA/glutamate neuro-
transmission. Therefore, the second part of this study
was focused on quantitative live-cell imaging investigating
synaptic vesicle recycling in primary hippocampal and
cerebellar neurons and electron microscopy to investigate
potential presynaptic structure differences in the cere-
bellum. These studies indicated differences in the dy-
namics of synaptic vesicle turn-over, and together with
the identified protein changes, we hypothesise that
disturbances of synaptic dynamics are linked to fragile
X syndrome.
Methods
Animal model
Fmr1 knockout (KO) mice and wild type (WT) littermates
on a congenic C57BL/6 background were provided by the
Clinical Genetics group at Erasmus MC, The Netherlands.
The mouse experiments were approved in advance by the
Fig. 1 Overview of experimental design. In the mass spectrometry studies, the Fmr1 KO mouse model was compared with WT mice. Frontal cortex,
hippocampal and cerebellar brain tissues were used for protein profiling using LC-MSE. For synaptosomes, both hippocampal and cerebellar tissues were
used for LC-MSE and SRM-MS studies. Data analysis resulted in the identification of significant protein changes. For live-cell imaging, neurons of the Fmr1
KO mouse model were cultured and compared with WT mice for both hippocampus and cerebellum. These neurons were stained with FM1-43 dye that
specifically stains synaptic vesicles. For electron microscopy, Fmr1 was specifically knocked down in Purkinje cells and these cells were used
for ultrastructural analysis. Data analysis was performed in instrument specific programmes, and statistical analysis was performed using R statistical
programming language
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Institutional Animal Welfare Committee (Erasmus MC,
Rotterdam, The Netherlands). Mouse brain tissue samples
used for LC-MSE experiments were obtained by crossing
FVB/Ant x heterozygous Fmr1 KO(2) to test hybrid mice
with 50 % FVB/Ant and 50 % C57BL/6 contributions [11].
Both lines were inbred (>10 times backcrossed). All mice
were male, aged 14 weeks old, with an average weight of
30.2 +/− 2.0 g for Fmr1 KO and 29.2 +/− 2.5 g for wild
type (WT) mice and were tested on the ErasmusLadder
(for data obtained with the ErasmusLadder see [12]). After
the training period, 11 Fmr1 KO and 12 WT male mice
were killed and the bilateral hippocampi, frontal cortices
and cerebella were dissected. All mice were sacrificed by
cervical dislocation, and brains were dissected immediately.
Fmr1 KO(2) mice and WT littermates [11] were used
to obtain synaptosomal fractions as described by
Schrimpf and colleagues [13]. Compared to the brain tis-
sue samples, the background of these mice was C57BL/6
and backcrossing occurred for more than 10 generations.
Synaptosomal fractions were obtained from the hippo-
campi (n = 10/group) and cerebella (n = 10/group), and
these samples were used for homogenization and step-
wise centrifugation to remove cell debris and to extract
the synaptosomes [13].
For neuronal cultures, E18 Fmr1 KO(2) and WT
mouse embryos with a C57BL/6 background [11] were
decapitated and both the hippocampi and the cere-
bella were dissected and used for neuronal cell culture
(see Additional file 1, page 22). For electron microscopy,
Purkinje cell-specific Fmr1 KO mice with a C57BL/6
background were generated via deletion of the first coding
exon of Fmr1 through Cre-mediated recombination, as
described by Koekkoek and colleagues [14].
Protein digestion
Sample preparation was performed as previously des-
cribed for both non-targeted and targeted studies (see
Additional file 1, pages 1–4) [15, 16]. In short, samples
were reduced and alkylated prior to tryptic digestion.
Quality control (QC) samples were created by pooling
all samples after alkylation.
Label-free LC-MSE protein profiling
Reverse-phase ultra performance-liquid chromatography
(UPLC), using C-18 columns, was coupled to a Q-TOF
Premier™ MS (Waters) system through a nano-electron
spray ionization (ESI) online emitter (see Additional file 1,
page 2). LC-MSE data was processed using ProteinLynx
Global Server v.2.5 (Waters Corporation) and Rosetta
Elucidator v.3.3 (Rosetta Biosoftware, Seattle, WA).
Criteria for protein identification were ≥3 fragment ions
per peptide, ≥7 fragment ions per protein and ≥2 pep-
tides per protein.
Targeted protein quantification
Candidate proteins, chosen based on in silico path-
way analyses of the LC-MSE results, as described in
Additional file 1, pages 1–15, as well as proteins as-
sociated with FMRP in the literature, were further
validated and quantified using targeted selected reac-
tion monitoring mass spectrometry (SRM-MS) on a
Xevo TQ-S mass spectrometer coupled to a nanoAcquity
UPLC system (Waters Corporation). Criteria for selecting
tryptic peptides were based on peptide count, uniqueness
and quality of transitions. Two peptides were selected for
each target protein and isotopically labelled peptides
were synthesised at JPT Peptide Technologies GmbH
(Berlin, Germany). At least three transitions were mea-
sured for each peptide, and each sample was analysed
in triplicate. Isotopically labelled synthetic peptides
were spiked into the samples as an internal standard
prior to MS analysis. The candidate proteins were vali-
dated and quantified with SRM mass spectrometry as
described previously [15]. Due to the observation that
most of the proteins identified in the initial LC-MSE
discovery study were located at the synapse, the proteomic
profiles of synaptosome fraction were investigated using
LC-MSE as well as SRM for validation purposes.
Statistical analysis of mass spectrometry data
Both LC-MSE and SRM data were analysed in the R statis-
tical programming language (version 3.1.1 [17]) using the
MSstats package (Purdue University; West Lafayette, IN,
USA), which provides wrapper functions to simplify the
fitting of linear mixed effects models. The data of the
identified proteins were log2 transformed and normalised
for the intensities of the peaks. For the label-free LC-MSE
experiment, constant normalization was performed based
on endogenous signals across runs among all proteins.
Peptide transitions were excluded based upon a between-
run-interference score <0.8, where the score was based on
the correlation between mean of peptide by run and
peptide transition intensity. Analysis was performed
using linear mixed models to detect differentially
expressed proteins between groups, as this approach
can handle the hierarchical structure of the data. The
interference for biological replicates and technical repli-
cates was used in expanded scope, which expands the
conclusion from the model to the population of bio-
logical units [18]. We considered results significant
when proteins were found to be changed by more than
10 % and with a p value <0.05. These analyses resulted
in p values, q values (Benjamini&Hochberg method)
and ratio changes (Fmr1/WT).
For SRM-MS analysis, proteins with a peptide count
(PC) >2, p value <0.05 and a ratio >10 % were
included. Difference from the LC-MSE analysis was
that constant normalization was performed based on
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reference signals across runs among all proteins, and
quantification was based on the ratio between en-
dogenous and reference intensity. Data was analysed
using a linear mixed model in restricted scope, which
limits the conclusion from the model to observed
biological units [18].
Furthermore, protein-protein interaction networks
were constructed from the significantly changed pro-
teins by finding first-degree interacting neighbours as
described in the Additional file 1, pages 16–21.
Analysis of live-cell imaging and electron microscopy
The synaptic boutons, visualized in primary neurons
as described in the Additional file 1, pages 22–25,
were analysed by identifying regions of interest (ROIs)
using Fiji [19]. Sample movement was corrected using
StackReg [20], and synaptic boutons were detected
and tracked using a semi-automated procedure imple-
mented in Fiji plug-in (available from http://smal.ws/
wp/software/sosplugin/[21]). Briefly, synaptic boutons
were detected by fitting Gaussian distributions with
sigma corresponding to bouton sizes ranging from
300–800 nm. To differentiate between synaptic bou-
tons and trafficking synaptic vesicles, tracks were
created using a nearest-neighbour linking approach
for objects moving less than 500 nm within three
frames. Tracks were visualized and quantified with the
MTrackJ plug-in of Fiji [22]. The identification of
different unloading profiles, the weak and strong
unloading synaptic boutons, was performed as described
before [23].
In R statistical programming language (version 3.1.1
[17]), the MTrackJ results and background values were
imported and relevant tracks were selected based on
starting time point and minimum time point length.
Baseline correction was performed by normalizing the
tracks for baseline intensity. To identify the two different
unloading profiles, tracks were hierarchically clustered
in sub-populations based on the decrease of signal im-
mediately after stimulation. The threshold criteria for
clustering were (1) a decrease of the slope after stimula-
tion of 25 %, (2) a relative amount of variation based on
a ratio stdev/mean intensity lower than 0.5 and (3)
stability of the baseline slope. Statistical analysis was per-
formed using a t test with permutations to look for
differences in the amount of synaptic boutons and ana-
lysis of variance (ANOVA) to compare the regression
lines of the synaptic bouton dye release.
Furthermore, the ultrastructural data obtained by
electron microscopy (Additional file 1, page 26) were
statistical analysed in R using a t test with permutations
(AZ length, presynaptic area and vesicle density) and
correlation (density with AZ length).
Results
Quantitative LC-MSE proteomic profiling of mouse frontal
cortex, hippocampus and cerebellum
LC-MSE profiling was carried out to determine the
effects of the absence of the FMRP protein in mouse
brain. Previous studies have indicated that the cerebel-
lum [14, 24] and hippocampus [7] are prominently
affected in FXS. Moreover, since frontal cortex dysfunc-
tion is known to play a key part in autism [25], we in-
vestigated the frontal cortex additionally. After data
filtering, the analysis resulted in the identification of 553
(frontal cortex), 705 (hippocampus) and 536 (cerebellum)
proteins, respectively. Following data quality assessment,
24 proteins were significantly different in the frontal
cortex, 14 in the hippocampus and 11 in the cerebellum
(Additional file 1, page 6). GO-enrichment analysis was
performed to detect first-degree neighbour proteins
using all significantly changed proteins with a ratio
Fmr1 KO/WT of >10 % (Additional file 1, page 16).
The significant findings of the profiling study were pre-
dominantly proteins located at the synapse, such as
ATPases and proteins important for neurotransmitter
signalling (Additional file 1, page 9).
Quantitative LC-MSE proteomic profiling of synaptosome
fractions isolated from the hippocampus and cerebellum
In the synaptosome fraction study, the hippocampus and
cerebellum were prioritised as these are predominantly
affected in FXS. LC-MSE analysis of mouse synaptosomes
resulted in the identification of 1114 (hippocampus) and
1040 (cerebellum) proteins, respectively. After data filter-
ing, the number of significant proteins were 23 (hippo-
campus) and 13 (cerebellum) (Additional file 1, page 11).
In GO enrichment, fewer networks are indicated for the
synaptosome fractions compared to brain tissue, as fewer
significant proteins were indicated (Additional file 1,
page 20). The main protein changes are involved in
synaptic signalling, neurotransmission, synaptic vesicles
and neuron development (Additional file 1, page 14).
Overlap of significantly altered networks between brain
tissue and synaptosome fractions indicated protein de-
phosphorylation and synaptic signalling, such as glutamate
pathways and dendrite morphogenesis, as changed in
common (Additional file 1, page 21). Therefore, proteins
involved in synaptic signalling as found in the protein
profiling study of the synaptosome fractions and in brain
tissue (Additional file 1, page 9, 14) were taken forward
for targeted SRM analysis.
Targeted SRM-MS validation of hippocampal and cerebellar
synaptosome fractions
An SRM-MS assay panel was developed to validate
changes related to signal transduction, neuronal develop-
ment and neurotransmission, including isoforms of the
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theme proteins and proteins known to relate to FXS from
the literature. The results show that most of the signifi-
cantly changed proteins in the hippocampus were de-
creased in abundance, while proteins significantly changed
in the cerebellum were increased (Table 1). In the hippo-
campus, a significant decrease was found for proteins
associated with neuronal development and GABA/glu-
tamate neurotransmission, as well as significantly different
levels of two ATPases. Most significant protein changes
were observed in the cerebellum, with a general increase
of abundance in ATPases and GABA/glutamate-related
proteins. Furthermore, several neuronal development
proteins were significantly different. FMRP-related pro-
tein CYFP1 was found to be significantly changed in
abundance in both the hippocampus and cerebellum,
while CYFP2 and FXR2 were only changed in the cere-
bellum (Table 1).
Identification of synaptic boutons using live-cell imaging
We could distinguish different unloading frequencies
of the synaptic boutons, which resulted in strong
(35 % intensity decrease after stimulation compared to
baseline) and weak (18 % intensity decrease) FM1-43
unloading profiles as described in Bartolome-Martin [23]
Table 1 Protein changes validated using SRM-MS in the mouse brain synaptosome fractions
HC CB
Protein name Ratio Fmr1 KO/WT p value q value Ratio Fmr1 KO/WT p value q value
Signal transduction
Plasma membrane calcium-transporting
ATPase 2 (AT2B2)a, b, e
1.11 0.6403 0.8270 1.16 0.2314 0.2953
Sodium potassium transporting
ATPase alpha 1 (AT1A1)a
0.99 0.8710 0.9194 1.32 2.60*10−11 3.20*10−10
Sodium potassium transporting
ATPase alpha 3 (AT1A3)a
0.74 0.0076 0.0480 1.66 2.50*10−07 1.03*10−06
Sodium potassium transporting
ATPase beta 1 (AT1B1)a
1.01 0.9524 0.9524 1.27 2.63*10−10 2.43*10−09
Sodium potassium transporting
ATPase beta 2 (AT1B2)a
1.21 0.0509 0.1874 1.19 0.0122 0.0215
Synaptic vesicle glycoprotein 2A (SV2A)b, d 1.02 0.6529 0.8270 1.20 0.0002 0.0005
Synaptic vesicle glycoprotein 2B (SV2B)b 0.86 0.1754 0.3715 0.92 0.5270 0.5909
Neuronal development
Brain acid soluble protein 1 (BASP1)c 0.77 <2.60*10−11 <2.60*10−11 1.75 8.15*10−07 3.02*10−06
Neuromodulin (NEUM)a 0.88 0.0751 0.1874 0.77 0.0071 0.0146
Neurotransmission: GABA/glutamate-related proteins
BTB POZ domain containing protein
KCTD12 (KCD12)a
0.73 0.38*10−05 0.0004 1.17 0.0098 0.0192
Glutamate receptor 1 (GRIA1)b, d 0.83 0.0789 0.1874 1.77 1.35*10−07 6.24*10−07
Glutamate receptor 3 (GRIA3)b, d 0.87 0.1760 0.3715 1.34 0.0160 0.0269
Succinate semialdehyde dehydrogenase (SSDH)a 1.06 0.3880 0.5897 0.93 0.3833 0.4432
Vesicular glutamate transporter 1 (VGLU1)a 1.02 0.8017 0.8934 1.23 0.0222 0.0342
Excitatory amino acid transporter 1 (EAA1)a 1.14 0.3178 0.5251 1.13 0.3431 0.4095
Glutamate decarboxylase 1 (DCE1)b 0.94 0.6107 0.8270 0.95 0.7279 0.7782
Glutamate decarboxylase 2 (DCE2)b, d 0.81 0.3422 0.5419 1.27 0.2416 0.2979
FMRP-related proteins
Cytoplasmic FMR1-interacting protein 1 (CYFP1)b, d 0.65 0.0205 0.0973 1.45 0.0437 0.0621
Cytoplasmic FMR1-interacting protein 2 (CYFP2)b 1.04 0.7761 0.8934 1.41 0.0217 0.0342
Fragile X mental retardation syndrome-related 2 (FXR2)c 1.04 0.7108 0.8713 1.26 0.0070 0.0146
* this is the multiply sign
The table includes Uniprot ID, ratios (calculated based on average), P values and adjusted P values (Q). Significant proteins are indicated in italics
aProteins indicated in LC-MSE brain study
bProteins indicated in LC-MSE synaptosome study
cProteins associated with FMRP in literature
dIsoforms of indicated proteins in B or S
eFamily member of proteins indicated in B or S
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(Additional file 1, pages 22–24). After identification of the
different unloading profiles, the number of synaptic bou-
tons was counted, which showed no differences in the
number of synaptic bouton unloading profiles in either
the hippocampus or the cerebellum (Additional file 1,
page 25). This result suggests that the number of synaptic
boutons in cultured neurons are comparable between the
Fmr1 KO and WT mice, and as dye loading and unloading
involve the same stimulation protocol (50 mM K+, 5 min),
any differences in unloading kinetics are likely to reflect
an alteration in synaptic vesicle dynamics.
Synaptic bouton dynamics in live-cell imaging
In live-cell imaging, the weak unloading boutons had
an intercept of 0.91 relative intensity (RI) (Fmr1 KO)
and 0.79 RI (WT) in the hippocampus and 0.81 RI
(Fmr1 KO) and 0.88 RI (WT) in the cerebellum. The
intercepts of the strong unloading boutons were 0.64 RI
(Fmr1 KO) and 0.61 RI (WT) for hippocampal neurons
and 0.41 RI (Fmr1 KO) and 0.59 RI (WT) for cerebellar
neurons. Determining the difference in rate of dye release
showed a significant decrease of both unloading profiles
in Fmr1 KO compared to WT mice in the hippocampus
(weak unloading boutons: p value = 0.004; strong unload-
ing boutons: p value = 0.008; Fig. 2). The synaptic vesicle
dynamics in the cerebellum showed a significant increase
of unloading activity in Fmr1 KO mice compared to WT
(weak unloading boutons: p value = 2.17 × 10−9; strong
unloading boutons: p value = 2 × 10−16; Fig. 2). This im-
plies that Fmr1 KO cerebellar neurons have a higher turn-
over rate of synaptic vesicle recycling.
Ultrastructural analysis of cerebellar Purkinje cells
Statistical t test with permutation of the labelled Purkinje
cell terminals (Fig. 3) was performed and showed no sig-
nificant difference for active zone (AZ) length (p value =
0.583), presynaptic area (p value = 0.357) and synaptic
vesicle density (p value = 0.543). When synaptic vesicle
density was correlated with the AZ length, we found a
negative correlation of r = −0.36 (p value = 0.206) for
Fig. 2 Differences in synaptic bouton unloading of FM1-43 dye in hippocampal (HC) and cerebellar (CB) neurons. (top left) Weak unloading boutons
are less synaptically active, which translates into the release of fewer synaptic vesicles and neurotransmitters. Strong unloading boutons have a greater
number of synaptic vesicle exocytosis and are therefore expected to release neurotransmitters more actively. Kinetics of FM1-43 unloading of weak
unloading boutons in the hippocampus showed a significant difference with a p value of 0.004 during stimulation with 50 mM KCl and (top right) a
significant difference with a p value of 0.008 for strong unloading boutons in the hippocampus. In the cerebellum, the weak unloading boutons
showed a highly significant change with a p value of 2.17 × 10−9 (below left), as well as a highly significant change with a p value of 2 × 10−16 for strong
unloading of FM1-43 dye from synaptic boutons (below right). The p values were obtained by regression analysis with ANOVA comparing Fmr1 KO
with WT mouse primary neurons
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the Fmr1 KO and a correlation of r = 0.059 (p value =
0.7364) for WT mice. These results imply that the
unloading activity at the synapse as observed in live-
cell imaging is caused by a higher turn-over rate of syn-
aptic vesicle recycling and not by an increased number
of synaptic vesicles.
Discussion
Here, we present a comprehensive study combining prote-
omic and microscopic investigations in an Fmr1 KO
mouse model. We employed orthogonal quantitative and
qualitative proteomic approaches, live-cell visualization of
synaptic vesicle dynamics and ultrastructural analyses of
synapses to investigate protein alterations and their func-
tional effects at the synapse in the context of FMRP
deletion. Our findings provide evidence that molecular
processes in synaptic transmission are affected in the
hippocampus and cerebellum of the Fmr1 KO mouse
model. Surprisingly, most of the significantly affected pro-
teins were identified in the cerebellum, which comprises
changes in proteins associated with signal transduction,
neuronal development and GABA/glutamate neurotrans-
mission. The finding that the cerebellum is a prominently
affected brain region is in line with behavioural findings
using the ErasmusLadder, demonstrating major deficits in
associative motor learning in Fmr1 KO mice [12]. In the
microscopy studies, we found that a lack of FMRP leads
to changes in synaptic vesicle unloading dynamics, with
a strong increase of synaptic vesicle turn-over in cere-
bellar neurons and a decrease in hippocampal neurons.
Fig. 3 Ultrastructural analysis of Purkinje cell synapses. Fmr1 KO (a) as compared to WT (b) Purkinje cell synapses revealed a negative correlation
of density vs. active zone (AZ) length in Fmr1 KO (c), while this was positive for WT (d). e–g No significant differences were observed for AZ length,
presynaptic area and vesicle density. In a and b: white rectangle= AZ; white circle= synaptic vesicles; and dark stained area= presynaptic area
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Therefore, alterations in synaptic vesicle dynamics due
to loss of FMRP likely contribute to aberrant synaptic
transmission in FXS patients. Recently, Myrick and
colleagues found protein synthesis-independent pre-
synaptic function for FMRP, using Drosophila melano-
gaster models with a missense mutation of a patient
with a partial FXS phenotype [26]. Our results together
with previous studies suggest that FMRP regulates
translation of proteins important for synaptic plasticity, in-
dicating that FMRP has specific pre-and postsynaptic
functions that contribute to different components of the
FXS pathophysiology [27].
The proteomic study showed that FMRP loss resulted
in changes in protein levels at the synapse, specifically
in proteins involved in signal transduction, neuronal
development and neurotransmission. The SRM-MS
study of the synaptosome fractions indicated that pro-
teins associated with signal transduction mainly relate
to ATPases, which are proteins that contribute to creat-
ing an ion gradient across the synaptic membrane and
therefore are important for synaptic transmission [28].
A functional link between glutamate action and ATPase
activity can be inferred from the observation that
glutamate, through metabotropic receptors, is able to
increase ATPase activity in Purkinje neurons [29]. In
the cerebellum, both the glutamate and GABA recep-
tors were increased in expression, whereas they were
decreased in the hippocampus, which might implicate
that the excitability of neurons is changed. Changes in
glutamate and GABA have been observed before in
fragile X animal investigations, resulting in the mGluR
theory and hypo-inhibition of GABA [7]. Moreover,
VGLU1, a protein that mediates the uptake of glutamate
into synaptic vesicles, and SV2A, important for fusion of
synaptic vesicles to the membrane, were significantly in-
creased in the cerebellum. A previous proteomic study
using primary Fmr1 KO hippocampal mouse neurons also
identified changes in the SV2A protein [30]. Other synap-
tic vesicle changes in the hippocampus indicate smaller
active zones and pools of clustered vesicles [31], a de-
crease of vesicle recruitment [8] and abnormal short-term
plasticity [10]. In addition, synaptic plasticity regulators
BASP1 and NEUM, which are important for synaptic
vesicle recycling, were found to be significantly changed in
both the hippocampus and cerebellum, of which BASP1 is
a consistent finding observed in previous studies in the
Fig. 4 Changes observed in hippocampal and cerebellar synapses using mass spectrometry and microscopy studies. In the hippocampus (above),
significant changes were observed for ATPases and a significant decrease of GABA receptor proteins. Furthermore, the microscopy studies
indicated decreased synaptic vesicle release in hippocampal neurons. This might indicate decreased excitatory synaptic transmission in the
hippocampus. A significant increase of ATPases, GABA and glutamate receptors and synaptic vesicle proteins were observed in cerebellar
synapses (below). This increase in synaptic activity was also supported by the microscopy studies, in which cerebellar neurons show an increase of synaptic
vesicle dynamics, suggesting an increased inhibitory output from the cerebellum
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hippocampus [31]. Overall, this proteomic investigation
provides evidence that loss of FMRP in the mouse brain
alters synaptic signalling due to changes the in regulation
of membrane potential and neurotransmitter release,
which is in line with previous findings [26]. Using SRM-
MS, we also found a significant change in the expression
of FMRP-associated protein CYFP1 [32], both in hippo-
campal and cerebellar synaptosome fractions. Changes in
FXR2 [33] correlated with changes in CYFP2 [32], which
could be due to their interaction [34].
Investigating synaptic transmission using microscopy
showed an increase of synaptic vesicle recycling in cere-
bellar neurons, which is held true for both boutons with
weak and strong unloading. The majority of cerebellar
neurons consist of Purkinje cells, which represent the
main GABAergic inhibitory neuronal output from the
cerebellum. An increase of synaptic vesicle recycling in
cerebellar neurons might represent an increase of inhibi-
tory output from the cerebellum. Since the amount of
synaptic vesicles, active zone length and presynaptic area
were not changed in the Purkinje cell axon terminals,
the changes in synaptic vesicle recycling is mainly dy-
namic. These findings raise the question to what extent
the enhanced LTD observed in Fmr1 KO Purkinje cells
[14] reflects a compensatory process rather than a pri-
mary defect. Indeed, it is possible that homeostatic
mechanisms through the olivocerebellar loop regulate
the level of synaptic plasticity in Purkinje cells so as to
stabilise the output of the cerebellar nuclei [35].
Decreased synaptic transmission in mouse amygdalae,
neocortex and rat dorsal root ganglia have been ob-
served before [36–38]. These studies together with the
increase in long-term depression (LTD), as stated by the
mGluR theory [7], imply a decrease of synaptic transmis-
sion in the FXS hippocampus. Interestingly, the study of
Deng (2011) suggested increased synaptic transmission
in the hippocampus, due to increased short-term plasti-
city (STP) [10]. However, Klemmer (2011) found re-
duced synaptic transduction resulting from a decreased
number of synaptic vesicles, a shorter active zone
length and a decrease of STP [31]. Recently, the study
of Telias et al. indicated fewer synaptic vesicles and
spontaneous synaptic activity in FXS human embryonic
stem cells [39]. In our study, we showed that FMRP de-
pletion causes a decrease of synaptic vesicle recycling
in both strong and weak unloading boutons in the
hippocampus, while the amount of synaptic boutons
remained unchanged between Fmr1 KO and WT mice.
Only male mice were investigated in this study. There-
fore, the proteomic changes relevant to ASD highlight
the changes seen in the male sex. Although only Fmr1
KO mice were investigated, differences in mouse genetic
background between the tissue and synaptosome sam-
ples (see “Methods” section) might influence the results.
Conclusions
Taken together, our findings demonstrate that a lack of
FMRP is associated with differences in synaptic vesicle
dynamics in both hippocampal and cerebellar neurons
(Fig. 4). Synaptic vesicles are critical for synaptic trans-
mission in the nervous system, and inefficient synaptic
transmission in the hippocampus and cerebellum could
impair memory formation and motor learning in fragile X
and possibly autism spectrum disorder (ASD) patients.
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fractions in LC-MSE and GO term enrichment results. (DOCX 405 kb)
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